Mode
Text Size
Log in / Sign up
N/A N=185 Randomized Single-blind Health Services Research

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Neonatal Opiate Withdrawal Syndrome

Enrolled (actual)
185
Serious AEs
1.2%
Results posted
Oct 2023
Primary outcome: Primary: Time From Birth Until Medically Ready for Discharge — 14.9; 8.2 days — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Finnegan Neonatal Abstinence Scoring Tool (Other); Eat, Sleep, Console (ESC) care tool (Other)
Age
Pediatric
Sex
All
Sponsor
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Primary completion
May 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Time From Birth Until Medically Ready for Discharge
14.9; 8.2 <0.0001 sig
SECONDARY
Did Infant Receive Opioid Replacement Therapy (Yes/no)
328; 145 <0.0001 sig
SECONDARY
Total Dose of Opioid Replacement Therapy Infant Received
7.5; 5.3
SECONDARY
Time Until Initiation of Opioid Replacement
53.0; 76
SECONDARY
Receipt of Adjuvant Therapy
19.4; 15.7
SECONDARY
Maximum Percent Change in Weight During Initial Birth Hospitalization
7.6; 8.0
SECONDARY
Feeding Type at Discharge (Exclusive Maternal Breast Milk)
6.3; 12.1
SECONDARY
Any Direct Breast Feeding at Discharge
19.5; 32.7
SECONDARY
Length of Hospital Stay
14.0; 7.8
SECONDARY
Inpatient Composite Safety Outcome Which Includes Seizures, Accidental Trauma, Respiratory Insufficiency Due to Opioid Therapy (Present/Absent)
1; 2
SECONDARY
Composite of the Following: Acute/Urgent Care and/or Emergency Room Visits, Hospital Readmissions
113; 86
SECONDARY
Critical Safety Outcome
5; 1

Summary

The overall objective is to determine if the ESC care approach will reduce the time until infants being managed for NOWS are medically ready for discharge.

Eligibility Criteria

Inclusion Criteria

  • 1. The infant is being managed for NOWS at an eligible site (i.e., receiving non-pharmacologic care, assessments for withdrawal severity, +/- pharmacologic care) 2. The infant is ≥ 36 weeks gestation 3. The infant satisfies at least 1 of the following criteria:
  • Maternal history of prenatal opioid use
  • Maternal toxicology screen positive for opioids during the second and/or third trimester of pregnancy
  • Infant toxicology screen positive for opioids during the initial hospital stay

Exclusion Criteria

  • 1. Infant has major birth defect(s) 2. Infant has neonatal encephalopathy (inclusive of hypoxic ischemic encephalopathy), a metabolic disorder, stroke, intracranial hemorrhage, or meningitis diagnosed by 60 hours of life 3. Infant was receiving respiratory support (any positive pressure or oxygen therapy) unrelated to pharmacologic treatment for NOWS at 60 hours of life 4. Infant was receiving antimicrobial(s) at 60 hours of life 5. Infant has received any major surgical intervention in the first 60 hours of life 6. Postnatal opioid exposure other than for treatment of NOWS in the first 60 hours of life 7. Outborn infants transferred at >60 hours of life or treated with opioids for NOWS at the transferring hospital
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04057820). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search